Challenges In Ser.: Challenges in Growth Hormone Therapy by John P. Monson (1999, Hardcover)

Wiley & Sons, Incorporated, John

0632051647

9780632051649

764786

John P. Monson

Challenges in Growth Hormone Therapy

Hardcover

English

Challenges in Ser.

1999

Textbook

320 Pages

9.6in

6.8in

26.7 Oz

Rc658.7.C47 1999

"This is an excellent book. It summarizes, in a concise yet reasonably comprehensive manner, the increasing literature on the theraputic use of growth hormone (GH) spawned by the recent availability of virtually unlimited quantities of GH obtained through recombinant DNA technology... the authors and the editor should be congratulated for assembling such a readable and yet comprehensive list". (Trends in Endocrinology & Metabolis Volume 11), "This is an excellent book. It summarizes, in a concise yet reasonably comprehensive manner, the increasing literature on the theraputic use of growth hormone (GH) spawned by the recent availability of virtually unlimited quantities of GH obtained through recombinant DNA technology... the authors and the editor should be congratulated for assembling such a readable and yet comprehensive list".(Trends in Endocrinology & Metabolis Volume 11)

1 GH replacement in children - what is the optimum dosing schedule?2 What is the current status of GH therapy in children with Turner's syndrome?3 Is there a role for GH therapy in Noonan's syndrome?4 Does GH therapy influence final height in skeletal dysplasia syndromes?5 Is there a role for GH therapy in short normal children?6 What is the role of GH therapy in children born small for gestational age?7 Is cardiovascular mortality increased in hypopituitary adults?8 How should we diagnose GH deficiency in hypopituitary adults?9 What is the impact of GH deficiency on bone density in childhood-onset and adult-onset GH deficiency, and how effective is GH replacement?10 Individual susceptibility and GH dosing regimen in adults11 What is the impact of GH deficiency and GH replacement on quality of life in childhood-onset and adult-onset GH deficiency?12 Is there an upper limit for GH replacement in hypopituitary adults?13 Is open-ended GH replacement a safe therapy?14 How should we evaluate GH treated patients at completion of linear growth?15 How should we transfer patients from paediatric to adult clinics?16 Is there a role for GH therapy in osteoporosis and in ageing?17 What is the current status of GH therapy in catabolic adults?18 Is GH therapy indicated in the metabolic syndrome?19 Does GH therapy have a role in management of cardiac failure?

1999

Life Sciences / Biochemistry, Endocrinology & Metabolism

99-017635

616.4/7061

Scholarly & Professional

21

Yes

Science, Medical